Browsing Leishmaniasis/Kala Azar by Authors

Now showing items 1-2 of 2

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

Wasunna, M; Njenga, S; Balasegaram, M; Alexander, N; Omollo, R; Edwards, T; Dorlo, TPC; Musa, B; Ali, MHS; Elamin, MY; et al. (Public Library of Science (PLoS), 2016-09-14)

SSG&PM over 17 days is recommended as first line treatment for visceral leishmaniasis in eastern Africa, but is painful and requires hospitalization. Combination regimens including AmBisome and miltefosine are safe and effective in India, but there are no published data from trials of combination therapies including these drugs from Africa.
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme

Kimutai, R; Musa, AM; Njoroge, S; Omollo, R; Alves, F; Hailu, A; Khalil, EAG; Diro, E; Soipei, P; Musa, B; et al. (Springer Link, 2017-01-09)

In 2010, WHO recommended a new first-line treatment for visceral leishmaniasis (VL) in Eastern Africa. The new treatment, a combination of intravenous (IV) or intramuscular (IM) sodium stibogluconate (SSG) and IM paromomycin (PM) was an improvement over SSG monotherapy, the previous first-line VL treatment in the region. To monitor the new treatment's safety and effectiveness in routine clinical practice a pharmacovigilance (PV) programme was developed.